Repositório Institucional da UFMG
metadata only
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
Contexto: A nitazoxanida está amplamente disponível e apresenta atividade antiviral de amplo espectro in vitro. No entanto, não há evidências de seu impacto na infecção pelo coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2). Métodos: Em um estudo multicêntrico, randomizado, duplo-cego
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Tabaquismo y Coronavirus#647075
- Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2#1384122
- A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2#1262389
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)#878893
- COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study#1138700
Record · ID 1481326
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive